• Haifeng Tang, Donghong Yang, Guoqing Luo, Jiaqi He, Guihua Yi, Zihong Chen, Haiwen Li, Qianbing Luo, Ningxin Huang, and Haiqing Luo.
• Specialty of Head and Neck Oncology at Cancer Hospital of the Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
• Medicine (Baltimore). 2023 Feb 17; 102 (7): e32924e32924.

RationaleLimited patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) have achieved complete response (CR) from induction chemotherapy (IC). Neoadjuvant immunotherapy combined with chemotherapy has marked therapeutic effects in some locoregionally advanced solid tumors. However, its efficacy and safety of NPC have not been reported so far. The rapid response of neoadjuvant tislelizumab combined with chemotherapy on LA-NPC may be associated with long-term survival benefit.Patient ConcernsA 57-year-old male patient presented with a 2-month history of bloody nasal discharge and right neck mass for 2 weeks.DiagnosisThe patient was eventually diagnosed with nasopharyngeal nonkeratinizing undifferentiated cell carcinoma (stage IVA).InterventionsThe patient received tislelizumab combined with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) nab-paclitaxel plus cisplatin for 4 cycles, followed by cisplatin-based concurrent chemoradiotherapy (CCRT).OutcomesA partial response (PR) was achieved after 2 cycles of tislelizumab and nab-paclitaxel plus cisplatin, and CR was achieved after 4 cycles of neoadjuvant treatment. The duration of response lasted 24 months, and the patient was still in CR as of November 2022. The patient had no serious adverse event (AEs) during the treatment.LessonsThis case report showed that tislelizumab combined with cisplatin plus nab-paclitaxel followed CCRT for treatment of patients with LA-NPC may receive a fast and durable response with a manageable safety profile and long-term survival.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

31 keywords...

hide…